Search clinical trials for: Insulin (glargine)

Total 2826 results

ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Completed

Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Type 2 Diabetic Patients | Insufficient Metabolic Control | OAD Treatment

Germany
Hoffmann-La Roche

Completed

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Diabetes Mellitus Type 2

Australia, Belgium, Hong Kong, United States, Germany, Portugal, Russian Federation, France, Canada, Finland, Austria, New Zealand, Spain, Poland, Thailand, Italy, Serbia, Korea, Republic of, Hungary, Mexico, Greece, Puerto Rico, Gu... and more
Sanofi

Completed

Insulin Glulisine in Type 2 Diabetic Patients (Basal Plus)

Diabetes Mellitus, Type 2

Russian Federation, United States, United Kingdom
Eli Lilly and Company

Recruiting

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

Cardiovascular Diseases | Obesity | Overweight | Type 2 Diabetes | Chronic Kidney Disease | Overweight or Obesity

United States, Italy, Spain, Korea, Republic of, India, Turkey, Austria, Puerto Rico, Mexico, Romania, Brazil, Germany, Argentina, Czechia, Greece, Slovakia
Eli Lilly and Company

Completed

A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

Type 2 Diabetes Mellitus

India
Eli Lilly and Company

Completed

A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany
Emory University

Completed

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery (SITA-CABGDM)

Hyperglycemia

United States
Sanofi
Population Health Research Institute

Completed

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)

Diabetes Mellitus, Non-Insulin-Dependent

United States, France, Brazil, Poland, Romania, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, India, Philippines, Russian Federation, Slovakia, Mexico, Argentina, Croatia, Austria, Denmark, Finland, Hungary, Lithuania, Norw... and more
Sansum Diabetes Research Institute
Novo Nordisk A/S

Completed

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. (SafrTravlT1D)

Diabetes Mellitus, Type 1

United States
Emory University
Merck Sharp & Dohme LLC

Completed

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Hyperglycemia | Type 2 Diabetes Mellitus | Hospitalization

United States
Fundación Pública Andaluza para la Investigación...

Completed

Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) (INEOX)

Type 1 Diabetes Mellitus

Spain
HealthPartners Institute

Terminated

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

DKA

United States
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

Diabetes Mellitus

Germany
Sanofi

Completed

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus (Pen Preference)

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Sanofi

Completed

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Type 2 Diabetes Mellitus

China
Emory University
Novo Nordisk A/S

Completed

Liraglutide Hospital Discharge Trial

Type 2 Diabetes

United States
University of Alabama at Birmingham

Recruiting

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

Diabetes Mellitus, Type 2 | Preterm Birth | Pregnancy, High Risk | Diabetes, Gestational

United States
Nanjing First Hospital, Nanjing Medical University

Unknown

Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus

Type2 Diabetes

China
University of the Highlands and Islands

Completed

The Acute Effects of Commercially Available Drinks on the Endothelial Function of Humans Following a High-fat Meal

Endothelial Dysfunction

United Kingdom
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study in Adults With Type 2 Diabetes (ELEMENT 2)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Mexico, Korea, Republic of, Germany, Poland, Taiwan, Spain, Greece, France, Czech Republic, Hungary
Sanofi

Completed

Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus (ATLAS)

Diabetes Mellitus, Type 2

Japan, Russian Federation, China, India, Pakistan, Philippines
The Coca-Cola Company

Completed

Evaluation of a New Orange-Based Beverage Enriched With Polyphenols in Adult Humans (BIONAOS)

Obesity | Overweight

Spain
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-5)

Diabetes Mellitus, Type 2 | Diabetes

Italy, Poland, Denmark, France, Netherlands, Austria, Spain, Finland, Argentina, India, Russian Federation, United Kingdom, Slovakia, Brazil, Norway, Former Serbia and Montenegro, South Africa, Philippines
AstraZeneca
Eli Lilly and Company

Completed

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Sweden, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Estonia, Romania, Finland, Netherlands, Argentina, Belgium, Germany, Portugal, United Kingdom, Greece, France, Puerto Rico
Northwestern University

Terminated

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Insulin Resistance, Diabetes | Hyperglycemia Steroid-induced

United States
Sanofi

Completed

Insulin Glargine Combination Therapies in Type II Diabetics (LAPTOP)

Diabetes Mellitus, Type 2

France, Germany, Netherlands, Spain, Sweden, Switzerland, United Kingdom, Finland, Italy, Austria
Eli Lilly and Company

Completed

A Study in Participants With Type I Diabetes Mellitus (IMAGINE 3)

Diabetes Mellitus, Type 1

United Kingdom, United States, Australia, Canada, Poland, Denmark, Spain, Croatia, Sweden, Greece, Belgium, France, New Zealand, South Africa, Israel, Brazil, Ireland, Netherlands, Lithuania, Slovakia
Eli Lilly and Company

Completed

A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants

Healthy

Singapore
Sanofi

Completed

Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy (TED)

Diabetes Mellitus, Type 2

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

Type 2 Diabetes Mellitus

China
University of Alabama at Birmingham
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

Type 2 Diabetes

United States
Hospital Central "Dr. Ignacio Morones Prieto"

Completed

Effects of Local Insulin on Varicose Ulcers for Wound Healing

Angiogenesis | Varicose Ulcer | Insulin | Wound Healing | Chronic Venous Disease

Mexico
Eli Lilly and Company

Completed

A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

Diabetes Mellitus

South Africa
Eli Lilly and Company

Completed

A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes (SPIRIT)

Type 2 Diabetes Mellitus

Ukraine
Geropharm

Completed

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Russian Federation
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
University of Guadalajara

Completed

Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus (Diabetes)

Type 2 Diabetes Mellitus

Mexico
Sanofi

Completed

Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)

Diabetes Mellitus, Type 2

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Austria, Switzerland, United Kingdom, Germany, Ireland
Eli Lilly and Company

Completed

A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Romania, Italy, Belgium, Poland, Greece, Germany, United Kingdom, Turkey, Czech Republic, Slovakia
Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more
Eli Lilly and Company

Completed

A Study in Participants With Type 1 Diabetes Mellitus (IMAGINE 1)

Diabetes Mellitus, Type 1

Japan, United States, Russian Federation, France, Mexico, Austria, Germany, Italy, Poland
Chungbuk National University Hospital

Active, not recruiting

Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus | Glucose, High Blood

Korea, Republic of
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Eli Lilly and Company

Completed

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Diabetes Mellitus, Type 2

Turkey, Argentina, Korea, Republic of, Brazil, China, Egypt, India, Spain
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark

Search clinical trials for: Insulin (glargine)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations